📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item
TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. While revenue remained relatively flat at ₹209.30 crore, the bottom line was severely impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. Segment-wise, the Consumer Products and Medical Devices divisions saw margin pressure, while the Protective Devices division continued to report losses. On a positive note, the Foods and Animal Welfare segments showed improved profitability during the quarter.
Key Highlights
Revenue from operations grew marginally by 2.2% YoY to ₹209.30 crore compared to ₹204.74 crore.
Net profit declined 37% YoY to ₹10.53 crore, primarily due to a ₹7.58 crore exceptional charge for labour code adjustments.
Consumer Products segment profit fell sharply to ₹2.25 crore from ₹6.45 crore in the previous year's quarter.
Protective Devices segment recorded a loss of ₹1.10 crore, widening from a loss of ₹0.31 crore YoY.
The company reconstituted its board committees following the retirement of Independent Director Mr. N Ramesh Rajan.
💼 Action for Investors
Investors should monitor the recovery in the Consumer Products segment and the narrowing of losses in the Protective Devices division. While the profit dip is largely due to a non-recurring regulatory charge, the underlying operational weakness in core segments warrants a cautious approach.
TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item
TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. The bottom line was significantly impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes affecting gratuity and leave provisions. While revenue from operations remained relatively flat at ₹209.30 crore, the Protective Devices segment continued to struggle, reporting a loss of ₹1.10 crore. Conversely, the Animal Welfare and Medical Devices segments showed healthy revenue growth during the quarter.
Key Highlights
Net Profit for Q3 FY26 fell 37% YoY to ₹1,053.26 lakhs compared to ₹1,673.24 lakhs in the previous year.
Revenue from operations grew marginally by 2.2% YoY to ₹20,929.89 lakhs.
Recognized a net exceptional charge of ₹757.87 lakhs due to the incremental impact of new Labour Codes on employee benefits.
Protective Devices segment reported a loss of ₹110.23 lakhs, continuing a trend of underperformance.
Animal Welfare and Medical Devices segments saw revenue growth of 15.5% and 19.1% YoY respectively.
💼 Action for Investors
Investors should monitor the recovery in the Protective Devices segment and the stabilization of margins following the one-time labour code adjustments. The stock may face short-term pressure due to the sharp decline in quarterly profitability.
TTK Healthcare Q3 Net Profit Falls 37% to ₹10.53 Cr Due to ₹7.58 Cr Exceptional Labour Code Charge
TTK Healthcare reported a marginal 2.2% YoY growth in revenue from operations to ₹209.30 crore for Q3 FY26. However, Net Profit declined significantly by 37% YoY to ₹10.53 crore, primarily impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. While the Foods and Animal Welfare segments showed improved profitability, the core Consumer Products and Medical Devices divisions faced margin pressure, and the Protective Devices segment continued to report losses.
Key Highlights
Revenue from operations grew slightly to ₹209.30 crore in Q3 FY26 from ₹204.74 crore in Q3 FY25.
Net Profit dropped 37% YoY to ₹10.53 crore, down from ₹16.73 crore in the same quarter last year.
Recognized a net exceptional charge of ₹757.87 lakhs for incremental Gratuity and Long-term Compensated Absences following new Labour Code notifications.
Consumer Products segment profit slumped to ₹2.25 crore from ₹6.45 crore YoY, indicating significant margin pressure.
Foods segment performed strongly with profit rising to ₹3.40 crore compared to ₹1.43 crore in the previous year's quarter.
💼 Action for Investors
The profit decline is largely attributed to a non-recurring regulatory accounting charge; however, the sharp drop in Consumer Products margins is a fundamental concern. Investors should monitor if the growth in the Foods segment can offset the volatility in the Protective and Consumer product divisions.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a veteran professional with nearly 40 years of experience, including a 30-year tenure within the TTK Group where he served as the CFO of TTK Prestige Ltd. The appointment is subject to shareholder approval via a postal ballot process, with voting concluding on January 24, 2026. His deep expertise in corporate finance, audit, and internal controls is expected to enhance the company's governance framework.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting December 22, 2025
Appointee previously served as CFO of TTK Prestige Ltd and has nearly 40 years of leadership experience in finance and audit
Shareholder approval to be sought through Postal Ballot with remote e-voting from December 26, 2025, to January 24, 2026
Final results of the postal ballot and director appointment confirmation expected by January 28, 2026
💼 Action for Investors
Investors should view this as a positive governance move, bringing in a seasoned financial expert familiar with the group's operations. No immediate portfolio changes are required.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan brings nearly 40 years of experience in finance and audit, having previously served as the CFO of TTK Prestige for nearly three decades. The appointment is subject to shareholder approval via a postal ballot process ending January 24, 2026. This move strengthens the board's financial oversight and governance, leveraging his deep familiarity with the TTK Group's operations.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting Dec 22, 2025.
The appointee has nearly 40 years of experience and served as CFO of group company TTK Prestige for 30 years.
Shareholder approval to be sought via Postal Ballot with e-voting concluding on January 24, 2026.
Mr. Sundaresan is a Fellow Member of the ICAI with extensive expertise in corporate finance, audit, and ERP implementation.
💼 Action for Investors
The appointment of a seasoned financial expert from the group's ecosystem is a positive step for corporate governance. No immediate action is required other than noting the strengthening of the board's oversight capabilities.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a seasoned professional with nearly 40 years of experience in finance and audit, including a 30-year tenure at TTK Prestige where he retired as CFO in 2020. The appointment is subject to shareholder approval via a postal ballot process scheduled to conclude on January 24, 2026. This appointment is expected to strengthen the company's financial governance and strategic oversight.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting Dec 22, 2025
Appointee brings 40 years of leadership experience and previously served as CFO of TTK Prestige Ltd
Shareholder approval to be sought through Postal Ballot with e-voting from Dec 26, 2025, to Jan 24, 2026
The board meeting was held on December 22, 2025, and concluded within 15 minutes
💼 Action for Investors
Investors should view this as a positive governance move given the appointee's deep financial expertise and familiarity with the TTK Group. No immediate portfolio action is required.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare Limited has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a veteran of the TTK Group, having served nearly three decades with the group and retiring as the CFO of TTK Prestige Ltd in 2020. The appointment is subject to shareholder approval through a postal ballot process, with voting concluding on January 24, 2026. This appointment is expected to strengthen the company's financial governance and audit frameworks given his 40 years of experience in finance and regulatory compliance.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting December 22, 2025.
The appointee brings nearly 40 years of experience and previously served as the CFO of TTK Prestige Ltd.
Shareholder approval will be sought via postal ballot with the final results to be declared by January 28, 2026.
Mr. Sundaresan is a Fellow Member of the Institute of Chartered Accountants of India (FCA) with expertise in ERP implementation and corporate restructuring.
💼 Action for Investors
Investors should view this as a positive governance move that brings deep institutional knowledge and financial expertise to the board. No immediate action is required as this is a routine high-level management appointment.